The extended recovery ring-stage survival assay is a scalable alternative for artemisinin susceptibility phenotyping of fresh <i>Plasmodium falciparum</i> isolates
Artemisinin partial resistance (ART-R) has emerged in eastern Africa, necessitating regular surveillance of susceptibility of <i>Plasmodium falciparum</i> to artemisinins. The microscopy-based ring-stage survival assay (RSA) provides a laboratory correlate of ART-R but is limited by low throughput and subjectivity of microscopic counts of viable parasites. The extended recovery ring-stage survival assay (eRRSA) replaces microscopy with efficient quantitative PCR (qPCR) readouts but has been studied only with culture-adapted <i>P. falciparum</i> clones. We measured susceptibility to dihydroartemisinin (DHA) after a 6-h incubation with 700-nM DHA, followed by culture without drug, by comparing survival with that of untreated controls by microscopy (the RSA) or qPCR (the eRRSA) and also performed standard growth inhibition (half-maximal inhibitory concentration [IC<sub>50</sub>]) assays for 122 <i>P. falciparum</i> isolates freshly collected in eastern and northern Uganda from March to July 2022. The median values for RSA survival, eRRSA fold change, and DHA IC<sub>50</sub> were 3.0%, 46.2, and 3.2 nM, respectively. RSA percent survival and eRRSA fold changes correlated strongly (Spearman correlation coefficient [<i>r</i><sub><i>s</i></sub>] = -0.7411, <i>P</i> < 0.0001), with modest associations between the presence of validated <i>P. falciparum</i> Kelch13 ART-R mutations (C469Y or A675V) and RSA (median survival 2.6% for wild type [WT] vs 4.1% for mutant, <i>P</i> = 0.01), or eRRSA (median fold change 63.4 for WT vs 30.9 for mutant, <i>P</i> = 0.003) results. Significant correlations were also observed between DHA IC<sub>50</sub> values and both RSA percent survival (<i>r<sub>s</sub></i> = 0.4235, <i>P</i> < 0.0001) and eRRSA fold changes (<i>r<sub>s</sub></i> = -0.4116, <i>P</i> < 0.0001). The eRRSA is a scalable alternative for phenotyping fresh <i>P. falciparum</i> isolates, providing similar results with improved throughput.
Authors
- Roland A. Cooper (ORCID: https://orcid.org/0000-0002-8437-9382)
- Lisa A. Checkley
- Jennifer Legac
- Melissa D. Conrad (ORCID: https://orcid.org/0000-0002-9984-8030)
- Thomas Katairo (ORCID: https://orcid.org/0000-0002-2002-8911)
- Stephen Orena
- Frida G. Ceja
- Samuel L. Nsobya (ORCID: https://orcid.org/0000-0003-4986-8823)
- Martin Okitwi (ORCID: https://orcid.org/0000-0003-2712-2174)
- Douglas A. Shoue (ORCID: https://orcid.org/0000-0003-4991-6039)
- Mackenzie A. C. Sievert
- Shreeya Garg (ORCID: https://orcid.org/0000-0002-0570-3595)
- Michael T. Ferdig (ORCID: https://orcid.org/0000-0003-3516-9829)
- Philip J. Rosenthal (ORCID: https://orcid.org/0000-0002-7953-7622)
- Patrick K. Tumwebaze (ORCID: https://orcid.org/0000-0002-5933-1432)
- Oriana Kreutzfeld (ORCID: https://orcid.org/0000-0003-2026-345X)
- Oswald Byaruhanga
- Yoweri Taremwa
- Jeffrey A. Bailey
Institutions
- University of Notre Dame (US)
- Dominican University of California (US)
- John Brown University (US)
- University of California, San Francisco (US)
- Brown University (US)
- University of California System (US)
- Infectious Diseases Research Collaboration (UG)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1128/aac.01183-24
- Citations
- 1
- Primary Topic
- Malaria Research and Control
- Type
- article
- Field-Weighted Citation Impact
- 0.54
Funders
- Bill and Melinda Gates Foundation